Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

"Declaration of personal interests Jan Tack has served as a scientific advisor for Addex pharma, AGI Therapeutics, Almirall, Aryx, AstraZeneca, Danone, Ipsen, Menarini, Movetis, Norgine, Novartis, Nycomed, Ocera, Rose Pharma, SK Life Sciences, Smartpill, Sucampo, Theravance, Tranzyme, Xenoport and Zeria, and a speaker for Abbott, AstraZeneca, Menarini, Movetis, Novartis and Nycomed. Michael Camilleri has served as a consultant and an advisory board member for Adolor, Albireo Pharma, Alkermes, Ardelyx, ARYx Therapeutics, Ascent, Astellas, AstraZeneca, BioKier, Biomedical Insights, Domain, GlaxoSmithKline, Ikaria, Ironwood, Johnson & Johnson, NovaSecta, Ocera, Procter & Gamble, Shire, SK Bio, Synergy, Takeda, Theravance and Tranzyme, and has received research funding from Albireo, NIH, Rose Pharma, Tsumura and Wyeth. Lin Chang has served as a consultant or an advisory board member for Prometheus Laboratories, Takeda, Albireo, Rose Pharma, GlaxoSmithKline, Ironwood, Forest, Salix, Marathon Pharmaceuticals, Novo Nordisk, Lexicon and Movetis, and has received research funding from Prometheus, Rose Pharma, Takeda, Ironwood and Shire. William D. Chey has served as a consultant and an advisory board member for Albireo, AstraZeneca, Forest, Ironwood, Procter & Gamble, Prometheus, Salix, Smartpill, Takeda, and has received research funding from Ardelyx and Ironwood. James J. Galligan has served as a consultant for Faegre and Benson (now Faegre, Baker, Daniels), and LLP. Brian E. Lacy has served as a speaker for Novartis, Prometheus and Takeda, and an advisory board member for Prometheus, Takeda, Ironwood and Movetis. Dr Lacy has received investigator-initiated, unrestricted funding from Takeda. Stefan Müller-Lissner has served as a speaker, a consultant and an advisory board member for Axcan, Boehringer Ingelheim, Falk Foundation, Janssen, Movetis, Menarini Farmaceutica, Movetis, Mundipharma GmbH, Novartis, Pfizer, Procter & Gamble, Sucampo Pharma and Zeria Pharma. Eamonn M. M. Quigley has served as a consultant and an advisory board member for Movetis. Dr Quigley has also served as an advisory board chair for Janssen. Jan Schuurkes is an employee of Shire. Joris H. De Maeyer is an employee of Shire. Vincenzo Stanghellini has served as speaker and advisory board member for Axcan, Danone, Janssen, Movetis, Nycomed, Norgine, Novartis, Pfizer, Sofar and Valeas. Declaration of funding interests: The writing or preparation of this paper was funded in part by Movetis; writing support (conducting searches and editing the manuscript) was provided by Kate Carpenter and Victoria Harvey of Choice Pharma, and was funded by Movetis. Jan Tack has served as a scientific advisor for Addex pharma, AGI Therapeutics, Almirall, Aryx, AstraZeneca, Danone, Ipsen, Menarini, Movetis, Norgine, Novartis, Nycomed, Ocera, Rose Pharma, SK Life Sciences, Smartpill, Sucampo, Theravance, Tranzyme, Xenoport and Zeria, and a speaker for Abbott, AstraZeneca, Menarini, Movetis, Novartis and Nycomed. Michael Camilleri has served as a consultant and an advisory board member for Adolor, Albireo Pharma, Alkermes, Ardelyx, ARYx Therapeutics, Ascent, Astellas, AstraZeneca, BioKier, Biomedical Insights, Domain, GlaxoSmithKline, Ikaria, Ironwood, Johnson & Johnson, NovaSecta, Ocera, Procter & Gamble, Shire, SK Bio, Synergy, Takeda, Theravance and Tranzyme, and has received research funding from Albireo, NIH, Rose Pharma, Tsumura and Wyeth. Lin Chang has served as a consultant or an advisory board member for Prometheus Laboratories, Takeda, Albireo, Rose Pharma, GlaxoSmithKline, Ironwood, Forest, Salix, Marathon Pharmaceuticals, Novo Nordisk, Lexicon and Movetis, and has received research funding from Prometheus, Rose Pharma, Takeda, Ironwood and Shire. William D. Chey has served as a consultant and an advisory board member for Albireo, AstraZeneca, Forest, Ironwood, Procter & Gamble, Prometheus, Salix, Smartpill, Takeda, and has received research funding from Ardelyx and Ironwood. James J. Galligan has served as a consultant for Faegre and Benson (now Faegre, Baker, Daniels), and LLP. Brian E. Lacy has served as a speaker for Novartis, Prometheus and Takeda, and an advisory board member for Prometheus, Takeda, Ironwood and Movetis. Dr Lacy has received investigator-initiated, unrestricted funding from Takeda. Stefan Müller-Lissner has served as a speaker, a consultant and an advisory board member for Axcan, Boehringer Ingelheim, Falk Foundation, Janssen, Movetis, Menarini Farmaceutica, Movetis, Mundipharma GmbH, Novartis, Pfizer, Procter & Gamble, Sucampo Pharma and Zeria Pharma. Eamonn M. M. Quigley has served as a consultant and an advisory board member for Movetis. Dr Quigley has also served as an advisory board chair for Janssen. Jan Schuurkes is an employee of Shire. Joris H. De Maeyer is an employee of Shire. Vincenzo Stanghellini has served as speaker and advisory board member for Axcan, Danone, Janssen, Movetis, Nycomed, Norgine, Novartis, Pfizer, Sofar and Valeas. Declaration of funding interests : The writing or preparation of this paper was funded in part by Movetis; writing support (conducting searches and editing the manuscript) was provided by Kate Carpenter and Victoria Harvey of Choice Pharma, and was funded by Movetis."